Featured content
From our partners
Oligonucleotide therapeutics safety considerations across drug development
2026-10-07T14:00:002026-10-07T14:00:002026-10-07T15:00:00Sponsored by WuXi AppTec
As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
Opinion and interviews
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Oligonucleotide therapeutics safety considerations across drug development
2026-10-07T14:00:002026-10-07T14:00:002026-10-07T15:00:00Sponsored by WuXi AppTec
As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
Meeting ethical & regulatory requirements when using human biological specimens
Building better therapeutic antibodies: the science, progress and problems to solve
Oligonucleotide therapeutics safety considerations across drug development
- Previous
- Next